HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

European Panel Recommends Against Neratinib for HER2-Positive Breast Cancer

February 23rd 2018

European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.

Dr. Borgen Discusses HER2 Blockade in Breast Cancer

February 22nd 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

Dr. Traina Discusses Neratinib in HER2+ Breast Cancer

February 17th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Take-Home Messages on Breast Oncology Advances

February 17th 2018

Immunotherapy for Triple-Negative Breast Cancer

February 17th 2018

PARP Inhibitors for BRCA-Mutated TNBC

February 17th 2018

Advantages with Nab-Paclitaxel in TNBC

February 17th 2018

Trastuzumab Deruxtecan for HER2+ Breast Cancer

February 17th 2018

HER2-Targeted Therapy for HER2 Low-Expressing Breast Cancer

February 17th 2018

Adjuvant Therapy for HER2+ Breast Cancer

February 17th 2018

Refining Neoadjuvant Chemotherapy for HER2+ Breast Cancer

February 17th 2018

Ovarian Suppression in Metastatic HR+ Breast Cancer

February 17th 2018

Neoadjuvant Therapy for HR+ Breast Cancer

February 17th 2018

The Role of Fulvestrant in HR+ Breast Cancer

February 17th 2018

Abemaciclib for HR-Positive Metastatic Breast Cancer

February 17th 2018

Quality of Life for Women with HR-Positive Breast Cancer

February 17th 2018

MONALEESA-7 Trial in Premenopausal HR+ Breast Cancer

February 17th 2018

Expert Highlights Evolving Options in HER2+ Breast Cancer

February 15th 2018

Tiffany A. Traina, MD, discusses her experiences with using neratinib and pertuzumab, and shares her excitement on the direction in which the HER2-positive breast cancer field is moving.

Blackwell Sheds Light on Recent Advances in HER2+ Breast Cancer

February 14th 2018

Kimberly L. Blackwell, MD, discusses novel agents and other recent advancements in the treatment paradigm of HER2-positive breast cancer.

Dr. Isaacs Discusses the Future of Treatment for HER2+ Breast Cancer

February 14th 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the future of treatment for patients with HER2-positive breast cancer.